GSK Acquires Exclusive Rights for Prostate Cancer Treatment
GSK plc and Syndivia, a private biotechnology company, have announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical antibody drug conjugate (ADC) for metastatic castration-resistant prostate cancer (mCRPC).
Approximately 1.4 million men worldwide are diagnosed with prostate cancer each year, with 10-20% developing advanced disease within five years.
- Targeted treatment options are limited for patients with mCRPC.
- Standard of care options may be difficult to access and can be poorly tolerated with modest efficacy outcomes.
Survival rates for these patients are low, with a 5-year survival rate of approximately 30% and a median survival of approximately two years.
No direct quote available in the text.
Author's summary: GSK acquires rights for prostate cancer treatment.
More News
- Smallest OLED Pixels So Far
- Elon Musk's Starlink makes India debut; establishes first office in Mumbai
- Bridges Ӏ Sector Snapshot – Creating connections - Cranes Today
- Massa F1 court case is irrational. But it makes perfect sense
- It's become expensive and delayed, but now it's here: the capital's new light rail
- WhatsApp Will Soon Let You Manage Storage on a Per-Chat Basis
- Dodgers’ Freddie Freeman ends 18-inning World Series Game 3 thriller
- Suspect in Charlie Kirk killing can wear street clothes in court amid ‘extraordinary’ attention | Fulton Sun
- Big batteries boom Down Under